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Résumé: 
Les réponses immunitaires innées et adaptatives déclenchées par une infection virale chez l'humain sont 
classiquement décrites comme une succession d'événements communs à tous les virns- la réponse innée, 
caractérisés par la libération rapide de cytokines antivirales et des chémokines, recrntant monocytes, NK et 
lymphocytes T vers le site d'infection, suivis par l'activation de l'immunité adaptative. Notre compréhension de 
la dynamique de ces mécanismes dynamiques est limitée chez l'humain. En effet, il existe peu d'études portant 
sur la cinétique et l'analyse quantitative de la réponse T spécifique au virns, parallèlement aux aspects plus 
qualitatifs de cette réponse (cytokines sériques produites lors de différentes infections virales, notamment). 
Méthode: 
Nous avons étudiés trois groupes de patients tous recrntés au cours de la phase aiguë d'une infection par le virns 
de la dengue (2S patients), le virns influenza A (13 patients) et le virns de l'hépatite B (HBV) (13 patients). 
Nous avons analysé le profil d'activation (CD3S, HLA-DR) et de prolifération (Ki-67, Bcl-2) des lymphocytes 
T CDS+ (par cytométrie de flux), de façon longitudinale à différents timepoints (depuis le début des symptômes 
jusqu'à rémission totale) en quantifiant 15 cytokines et chémokines (par Luminex multiplex biometric 
immunoassay) dans le sérnm des patients infectés. 
Résultats: 
Nous avons comparé le profil des réponses innée et adaptative chez les 3 types d'infection virales; les patients 
infectés par l'HBV ont une fréquence élevée de CDS+ spécifiques activés et proliférant ainsi que des taux 
sériques élevés de TNF-a et d'IFN-y. Les patients infectés par le virns de la dengue et par le virns Influenza 
présentent quant à eux une activation CDS+ moins intense mais une forte expression de la réponse innée, 
marquée par une élévation des cytokines IFN-a, IFN-y, et TNF-a. De plus, une particularité des patients infectés 
par le virus de la dengue est de présenter une élévation marquée des cytokines immunorégulatrices (IL-10, IL-
lRA). 
Conclusion: 
Ces résultats permettent de montrer que la réponse immunologique consécutive à une infections virale 
spécifique est caractérisée par sa propre signature, tant au niveau de la production de cytokines/chemokines que 
de la quantité des lymphocytes T CD+S+ spécifiques activés et proliférantes. Ce travail contribue ainsi à une 
meilleure compréhension de l'immunité antivirale chez les humains, grâce à la description de la cinétique et de 
la quantification des cellules T CDS+ activées et des taux de cytokines dans chaque infection étudiée. 
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Abstract 
Knowledge of innate and adaptive immune parameters triggered by viral infections is limited 
but important for understanding disease pathogenesis. We performed a comparative 
longitudinal analysis of serum cytokines/chemokines and of virus-activated CD8 T cells 
population in patients with acute dengue, influenza A or HBV infections from onset to disease 
recovery. We observed that each viral infection is characterized by its own signature of 
cytokines/chemokines production and size of activated and proliferating CD8 T cell pool. 
This is, to our knowledge, the :first comparative longitudinal study of the immune response in 
human subjects in three distinct viral infections. 
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Introduction 
The sequential activation of different components of innate and adaptive immune systems 
characterizes the host response to viral infections. Anti-viral cytokines are rapidly produced 
and inhibit initial viral spread; chemokines and inflammatory cytokines recruit distinct 
immune cells (monocytes, NK and T cells) to the infection site; adaptive immunity through 
activation of B and T cells blocks viral re-infection and lyses virus-infected cells. Our 
understanding of these dynamic mechanisms is, however, limited in human acute viral 
infections and few reports have attempted to compare the kinetics and quantity of different 
cytokines produced in response to different viral infections [13]. Even more problematic is the 
quantitative comparison of virus-specific T cell response triggered by different viral 
infections. Virus-specific CD8 T cell response have been extensively analyzed in several viral 
infections ( e.g. HBV, HCV, HIV, EBV, HCMV), but these studies have focused on the 
dynamics of expansion and function of cells with few or selected specificities [15],[9]. 
Information related to the global repertoire of virus-specific CD8 T cells is thus lacking. Such 
lack of information is due to the fact that the overall magnitude of CD8 T cell response 
triggered by acute viral infections in human is difficult to measure. Quantification of virus-
specific T cells using peptide/HLA-class I pentameric complexes is often restricted by HLA 
types, while analysis using functional read-outs (ELISPOT, or intracellular cytokine staining) 
underestimate virus-specific T cells due to their potential dysfunctional state [ 5], [ 15]. 
To overcome these limitations, a recent work indicated that the whole population of bona fide 
virus-specific effectors CD8+ T cells can be identified using a combination of activation and 
proliferation markers (CD38, HLA-DR, Ki-67 and Bcl-2)[9]. We have recently observed that 
the CD8 T cell population expressing these markers can be inflated by the concomitant 
activation of CD8 T cells specific for persistent viruses like HCMV and EBV [12]. 
Nevertheless, such an approach can provide a good estimate of the size of effector CD8 T 
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cells activated by virus. By using these phenotypic markers on CD8 T cells and serum 
quantification of different analytes, we compared innate and adaptive immunity profiles in 
patients acutely infected with dengue, influenza A and HBV from onset of disease to 
recovery, we observed that each viral infection is characterized by preferential production of 
peculiar cytokines and chemokines and by differences in the quantity of CD8 T cells activated 
by the distinct viral infections. 
5 
Material and methods 
Patients 
Samples were taken from patients attending clinics for fever (~38°C) or jaundice within 72 
hours from illness onset. Sequential verrous blood samples were collected at enrolment (1 st 
visit), 4-7 days (2nd visit), and 3-4 weeks (3rd visit) after illness onset. A positive finding on 
RT-PCR for dengue or direct immunofluorescence on nasal swab for M protein of influenza 
A virus were taken as diagnostic for dengue and influenza, respectively. Positive HBsAg, IgM 
anti-HBc, and HBV-DNA, as well as ALT> 1000 U/L were diagnostic for acute hepatitis B. 
Peripheral blood mononuclear cell isolation was performed within 4 hours of drawing, and 
analyzed immediately or frozen for subsequent analysis. 
Phenotypical analysis 
Phenotypical analysis was performed on the PBMCs usmg surface markers CD3, CDS, 
activation markers HLADR and CD38, and intracellular markers Ki-67 and Bcl-2 as 
described previously [1]. 
Cytokine detection assay 
The following cytokines and chemokines were measured using a Luminex multiplex 
biometric immunoassay (Bioplex Human Cytokine Assay, Bio-Rad): IFN-a, IFN-y, TNF- a, 
IL-8, IL-1~, IP-10, IL-10, MCP-1, MIP-la, MIP-1~, IL-lRa, IL-7, IL-15, IL-2, IL-4 and IL-
12, according to manufacturer's instructions. Data analysis and graphs were made using 
GraphPad Prism 5.1 (GraphPad, US). 
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Results and discussion 
Quantification of plasma levels of multiple cytokines and chemokines 
Longitudinal samples were collected from patients attending clinics for high fever (~ 38°C) or 
jaundice although the onset of symptoms (fever in dengue and influenza infections, jaundice 
in HBV infection) represents different virological periods in the evolution of these distinct 
infections. While fever is likely to be directly triggered by the initial surge of viral replication 
in dengue and influenza infections, jaundice is the result of liver damage which occurs several 
weeks ( 4-6 weeks) post HBV infection, well after the peak of HBV repli cation period and at 
the time of circulating HBV-specific CDS T cells top frequency [ 1] . Direct quantification of 
HBV and dengue viremia further confirms this interpretation (supplementary Figure 1). 
Fifteen cytokines and chemokines were longitudinally measured in 13 patients with influenza 
A (7 H3, 3 Hl, 3 undetermined), 28 with Dengue (7 serotype 1, 21 serotype 2) and 13 with 
HBV infections and in samples of 5 healthy donors. Analyte levels were deemed elevated if 
their value was at least twice the mean level found in normal controls (table 1 a). Among the 
16 factors tested 5 (TNF-a, IFN-y, IL-1 RA, IL-10, CXCL-10) were elevated in more than 
50% of the patients irrespective to their etiology). Other analytes were instead more pathogen 
specific. For example, MCP-1 was frequently elevated in dengue and influenza infected 
subjects but their value was normal in patients with acute hepatitis B, which on the contrary 
present specific elevation of IL-8. 
We then evaluated the relative magnitude of the different cytokines triggered by the different 
pathogens (table 1 b). Even though the levels of most analytes increased in all patients 
irrespective of their infections, the three infections were characterized by the preferential 
increase of defined specific factors. IFN-a, TNF-a, IFN-y and IL-8 levels were maximally 
elevated in patients with acute hepatitis B, while the levels of immunoregulatory factors IL-
RA and IL-10, in addition to IL-12 p70 and CXCL-10 were higher in dengue patients than 
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HBV and influenza infected ones. The inflammatory, anti-viral cytokines (IFN-a, IFN-y, and 
TNF-a) and IL-8 in HBV were highest at the 1 st visit and dropped suddenly at the 2nd visit 
(Fig 1 a). Such high levels are likely due to the concomitant activation of adaptive immunity 
and of the liver damage while it is unlikely to derive from the direct stimulation of HBV. 
Previous studies performed in the early phases of HBV infections, before the onset of 
symptoms have shown that IFN-a, TNF-a and IFN-y were barely detectable [4], [13] while 
increased values of IFN-a were always detected in association with liver damage [14]. The 
production kinetic and the duration of elevation of cytokines/chemokines in influenza and 
dengue infections were instead different than those detected in HBV infected patients. Only 
two factors (IL- IRA and MCP-1) were higher at the 1 st visit than other time points. The 
majority of analytes measured had similar concentrations at 1 st and 2nd visits ( e.g. IFN-a, 
TNF-a, IFN-y) and in dengue infection higher concentrations of IL-10 and CXCL-10 were 
measured at 2nd compared to the 1 st visit, coinciding with the period when dengue viremia 
wanes. 
It appears plausible that, in contrast to HBV, the serum cytokines are the product of cells 
directly infected with either dengue or influenza virus, We have not performed in vitro tests to 
support this, but past studies have shown that Influenza infected epithelial cells have been 
shown in past studies to produce high levels of proinflammatory cytokines at the site of 
infection (IFN-a, TNF-a and IL-lp) [7]. The preponderance of cytokines produced by cells of 
the monocytes/dendritic cell lineage in dengue (IL12p70, MCP-1, IL-10) is in line with the 
demonstration that these cells are the primary target of dengue infection [2]. Moreover, 
dengue infected dendritic cells have been shown to produce high levels of IL-10 [ 11] . 
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Measure of T cell activation and prolif eration 
Having detected distinct pattern of soluble factors present in the serum of patients, we then 
compared the evolution of adaptive immune response by measuring ex vivo CD38/HLA-DR 
and KI-65+/ bcl-2 low CD8 + T cell frequency in patients in whom both serum and PBMC 
were longitudinally available (12 patients with acute hepatitis B, 12 patients with influenza 
and 12 with acute dengue infections) (Figure 1 c). 
Expansion of activated and proliferating (Fig 1 b) CD8+ T cell was detectable during all three 
infections, but differences in magnitude and kinetics were evident. A remarkably large 
expansion of activated CD8+ T cell pool was observed in patients with acute hepatitis B. 
CD38/HLA-DR markers were expressed by about a quarter of total CD8+ cells (mean 24%, 
range 13-35%) at the onset of clinical hepatitis B. In parallel with the drop of serum cytokines 
detected in the serum (IFN-y, TNF-a) (Fig la), the frequency of CD38/HLA-DR+ CD8+T 
cells decreased consistently at the second time point (8-10 days later, 12% of total CD8 in 
different patients; range 4-18%) and at the time ofrecovery it returned to the level (0.5 -3% of 
total CD8+), which could be found in healthy control subjects (Fig 1 b). Thus the kinetic 
profile of activated/proliferating CD8 T cells in HBV follows the quantity of serum cytokines 
detected in the serum, further supporting the hypothesis that the cytokines storm detected in 
these patients is a direct consequence of the activation of adaptive immunity. 
In patients with acute influenza and dengue infections, the frequency of activated CD8 T cells 
present was less abundant than in HBV infected patients, but activated CD8 T cells frequency 
was still more than ten times higher than those found in healthy controls. The peak frequency 
of activated CD8 T cells was detected in both infections at the second visit, consistent with 
the maturation time of adaptive immunity. Of note, the frequency of activated CD8 T cells 
detected in dengue infected subjects was similar to the one recently reported in subjects 
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vaccinated with yellow fever vaccine [9]. CDS+ T cells co-expressing Ki-67 and low Bcl-2 
followed an identical kinetic, but their frequencies were usually lower to the ones of CDS+ 
cells co-expressing HLA-DR and CD3S markers. 
Interestingly, when we calculated the overall quantity of the global activated CDS T cell 
population present in the blood of the patients, we observed that due to the marked 
lymphopenia present in patients with dengue infections, the mean lymphocyte counts at 2nd 
visit were lower in dengue (S45/ul) compared to either influenza (2033/ul) (p=0.0097) or 
acute hepatitis B (2000/ul) (p=0.0092). This indicates that the quantity of activated and 
proliferating CDS T cells present in dengue-infected patients was reduced in comparison to 
those detected in patients with acute HBV or influenza infections (Fig 1 b). 
The severe lymphopenia detected in dengue infection might be the consequence of the 
inhibitory effect of IL-10 on the expansion of virus-specific CDS cells and/or of the possible 
tissue re-distribution elicited by chemokines, in particular CXCL-10 [ 6] . IL-10 is a cytokine 
known to play an inhibitory role in the initial phase of proliferation of CDS T cells and has 
been associated with the establishment of a generally reduced level of memory T cell 
response [ 10], [3]. CXCL-10, orchestrates cell recruitment (mainly NK and T cells expressing 
CXCR-3 R) on the site of infection [6]. 
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Conclusion 
In conclusion, the comparative analysis of innate and adaptive immune parameters in three 
distinct viral infections showed that distinct signatures of anti-viral immunity are triggered by 
distinct viruses. The most striking feature detected in HBV infected patients is the robust 
involvement of CDS T cell response. Frequency of activated/proliferating CDS T cells are 
extremely high in comparison to other infections and are paralleled by high concentrations of 
TNF-a and IFN-y. Perhaps, such robust involvement of adaptive immunity is directly 
dependent on the weak early innate immune response present during HBV infection [1] . 
Accumulating evidences are showing that innate immune mechanisms might have a 
regulatory role on the size of adaptive immunity [S]. Influenza and dengue infections are 
instead characterized by a less intense activation of the CDS T cell compartment but robust 
innate immune responses. However, while the results obtained in influenza-infected patients 
did not reveal any peculiar elevations of distinct cytokines and chemokines, the analysis of 
dengue infected patients depict a cytokine/chemokine signature (MCP-1, CXCL-10, IL-10) 
that might play an important role in the dengue pathogenesis of disease. 
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Table 1. Cytokine levels in patients with HBV, influenza A or dengue virus infection and 
healthy controls. A. Frequency of patients with elevated levels of each analyte. Cytokine 
elevation was defined by mean cytokine levels equal or superior to 2. B. Mean values of the 
highest recorded level of each analyte. The highest level of analyte at any of the timepoints 
was recorded in each patient and the means were calculated for each patient group (hepatitis 
B, influenza A, dengue) and healthy controls. 
Table la 
FREQUENCY OF PATIENTS WITH ELEV ATED 
LEVELS OF EACH ANAL YTE 
Analyte 
IFN- a 
TNF-a 
IFN-y 
IP-10 (CXCL-10) 
MCP-1 
MIP-la 
MIP-1~ 
IL-8 (CXCL-8) 
IL-10 
IL-IRA 
IL-1~ 
IL-7 
IL-15 
IL-2 
IL-4 
IL-12 (p70) 
% of subjects with elevation 
HBV 
(n=13) 
80 
100 
80 
100 
0 
0 
100 
100 
100 
100 
40 
40 
100 
40 
0 
13 
Influenza A 
(n=13) 
46 
100 
100 
100 
61 
30 
15 
15 
100 
100 
0 
30 
23 
62 
0 
46 
Dengue 
(n=28) 
96 
100 
100 
100 
85 
96 
11 
39 
100 
100 
18 
35 
100 
53 
7 
61 
NOTE. - Cytokine elevation was defined by mean cytokine levels 
equal or superior to 2. 
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Table lb 
MEAN VALUES OF THE HIGHEST RECORD ED 
LEVEL OF EACH ANAL YTE 
Analyte Mean level Mean highest measured level (pg/ml) 
in Healthy 
controls HBV Influenza A Dengue (n=5) (n=l3) (n=l3) (n=28) (pg/ml) 
IFN-a 0.05 31 5 11 
TNF-a 1.03 42 9 30 
IFN-y 1.03 79.6 9.8 39 
IP-10 (CXCL-10) 198 3233 3453 7955 
MCP-1 58 78.7 114 357 
MIP-la 85 275 114 131 
MIP-1~ 0.01 0.01 0.1 9 
IL-8(CXCL-8) 8.1 63 10 20 
IL-10 1.01 17.7 21 143 
IL-IRA 45.9 301 604 1786 
IL-1~ 0.6 1.09 1.4 1.5 
IL-7 3.2 5.09 5.3 5.9 
IL-15 1.8 6.08 5.7 11.5 
IL-2 0.1 3.8 1 2 
IL-4 0.03 0.1 0.1 0.14 
IL-12 (p70) 0.6 1.2 2.6 8.2 
NOTE. - The highest level of analyte at any of the timepoints was recorded in each 
patient and the means were calculated for each patient group (HBV, Influenza A, 
Dengue, healthy controls). 
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Figure 1. Longitudinal comparison of serum cytokines and activated and proliferating 
CDS+ T cells in HBV, influenza A or dengue virus infection and healthy controls, from 
the onset of symptoms to convalescence. 
A. Longitudinal comparison of serum cytokines and chemokines in 13 HBV, 13 Influenza A, 
and 28 Dengue patients. Results are shown as mean concentration (pg/ml) +- SEM. B. 
Frequencies and numbers of activated (CD38+/HLA-DR+) and proliferating (Bcl-2low/Ki-
67+) CD8+ T cells from onset to recovery. Results expressed as Means +/-SEM. 
B. C. F ACS dot plots of representative patients with dengue, HBV or influenza A infection 
were gated on CD3/CD8+ cells. Note that the 12 patients with influenza and the 12 dengue 
infections studied here were comprised within the population of patients tested for serum 
cytokines. In contrast, of the 12 patients with acute hepatitis studied for T cell activation the 
data of corresponding serum cytokines is available only in 9. 
Supplementary Figure 1. Viremia quantification in Dengue (n=28) and HBV (n=l2). A. 
Dengue viremia (RNA copies/ml) from the onset of symptoms to recovery. The peak of 
Dengue viremia occurs at the onset of symptoms. B. HBV viremia (DNA copies/ml). Bars 
indicate the mean serum ALT levels. Peak of HBV viremia occurs at the onset of symptoms, 
which corresponds to the peak of ALT levels. 
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Abstract 
Herpesviruses infect most humans. Their infections can be associated with pathological conditions and significant changes 
in T cell repertoire but evidences of symbiotic effects of herpesvirus latency have never been demonstrated. We tested the 
hypothesis that HCMV and EBV-specific CDS T cells contribute to the heterologous anti-viral immune response. Volume of 
activated/proliferating virus-specific and total CDS T cells was evaluated in 50 patients with acute viral infections: 20 with 
HBV, 12 with Dengue, 12 with Influenza, 3 with Adenovirus infection and 3 with fevers of unknown etiology. Virus-specific 
(EBV, HCMV, Influenza) pentamer+ and total CDS T cells were analyzed for activation (CD3S/HLA-DR), proliferation (Ki-67 /Bcl-
210wl and cytokine production. We observed that ail acute viral infections trigger an expansion of activated/proliferating CDS 
T cells, which differs in size depending on the infection but is invariably inflated by CDS T cells specific for persistent 
herpesviruses (HCMV/EBV). CDS T cells specific for other non-related non persistent viral infection (i.e. Influenza) were not 
activated. IL-15, which is produced during acute viral infections, is the likely contributing mechanism driving the selective 
activation of herpesvirus specific CDS T cells. ln addition we were able to show that herpesvirus specific CDS T cells 
displayed an increased ability to produce the anti-viral cytokine interferon-y during the acute phase of heterologous viral 
infection. Taken together, these data demonstrated that activated herpesvirus specific CDS T cells inflate the activated/ 
proliferating CDS T cells population present during acute viral infections in human and can contribute to the heterologous 
anti-viral T cell response. 
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Introduction 
Over the course of the human lifetime, we are exposed to and 
infected by many different organisms which may be eliminated or 
may persist. The co-existence of microorganisms in humans is 
mainly perceived to have negative consequences for health and 
wellbeing, but examples of potential symbiotic relationship 
between the hast and microbes start to be recognized [1,2]. 
Classic examples of microorganisms establishing persistent 
infections in humans are Epstein Barr virus (EBV) and human 
cytomegalovirus (HClVIV) which are bath from ubiquitous 
herpesviridae family of viruses which infect more than 90'% of the 
human populations. These viruses are associated with the 
development of specific tumors (i.e. Burkitt's Lymphoma) and 
they can reactivate with significant pathological consequences in 
immunocompromised hasts [3,4]. Nevertheless, in most of the 
cases, herpesvirus infections are subclinical and well tolerated, 
even though they cause a robust distortion of T ce!! repertoire 
[5,6] with HCMV and EBV-specific CDS T ce!! known to 
represent up to 20% of total CDS T cell population [7,S,9]. Our 
inherent effort to maintain such a large population of virus-specific 
T cells, is seen as a necessity to suppress CMV and EBV 
reactivation in humans [9, 10, 11]. This would imply that the sole 
·:(fi).: PLoS Pathogens 1 www.plospathogens.org 
fonction of herpesvirus specific memory effector CDS T cells is to 
act against ClVIV and EBV infected cells. However, evidence in 
animal models have shown that effector or memory CDS T 
cells can provide immune protection against infection with 
unrelated intracellular pathogens through production oflnterfcron 
y (IFN-y) [12]. Such data open the possibility that the large 
population of HCMV and EBV-specific CDS T cells present in 
humans might contribute to the immunological response against 
other pathogens. 
Thus, we set out to evaluate whether CDS T cells specific for 
herpesviruses can contribute to the anti-viral T cell response 
triggered by heterologous acute viral infèction in humans. CDS T 
cell responses to acute viral infections were analyzed sequentially 
(from onset to recovery) by measuring the population of activated/ 
proliferating CDS T cells in patients with acute Hepatitis B Virus 
(HBV), influenza, dengue and adenovirus infections. The 
combination of activation and proliferation markers (CD3S, 
HLA-DR, Ki-67 and Bcl-2) expressed by CDS T cells have been 
recently proposed to identify the whole population ofvirus-specific 
effector CDS T cells induced by viral infection [13]. These results 
were obtained in subjects receiving attenuated virus vaccines 
(Smallpox and Yellow Fever), and activation (CD3S/HLA-DR) 
and proliferation markers (Ki-67 /Bcl-2 low) were only expressed 
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Author Summary 
The majority of humans are infected by herpesviruses, 
such as Epstein-Barr virus and Human Cytomegalovirus, 
which rarely cause severe pathology but heavily distort the 
human T cell repertoire. Up to 20% of cytotoxic T cells can 
be specific to Epstein-Barr and Cytomegalovirus. lt is 
believed that ail these herpesvirus specific T cells are 
needed to contrai the persistent infection. However, it has 
not been explored whether these T cells can contribute to 
the immune response to a new viral infection. To 
investigate this possibility, we analyzed the volume of 
activated virus-specific and total T cells in patients with 
acute hepatitis B, dengue, influenza and adenovirus 
infections. We observed that ail acute viral infections 
trigger an expansion of activated T cell population, part of 
which is specific to infecting agent, and the other part to 
herpesviruses. Our study provides evidence that persistent 
herpesvirus infections alter the composition of the T cell 
population which is activated during new acute viral 
infection. 
by CDS T cells specific for the vaccine but not by CDS T cells of 
different specificities. 
In contrast, we demonstrate here that acute symptomatic viral 
infections trigger an expansion of activated/prolilèrating CDS T 
cell populations of variable sizes, comprising CDS T cells specific 
for the infecting virus but these populations are also invariably 
inflated by CDS T cells specific for persistent herpesvirus 
infections. The increased sensitivity of HClVIV and EBV-specific 
CDS T cells to IL-15 is the likely explanation of this in vivo 
observation. In addition, HCMV and EBV specific CDS T cells 
demonstrate, at the peak of acute infection, an incrcased ability to 
secrctc IFN-y suggesting that they might functionally contribute to 
the heterologous acute anti-viral immunity. 
107 
106 
105 
HBV-DNA 104 
Copies/ml 103 
102 
+ 0:: 
On set 
28.3% 
40 
Day 7 
0 CD38/HLA-DR+ ~ 
:c 30 
03 
C'l 
0 20 ü 
+ OO 
0 10 ü 
"#. 
Heallhy Onset +7 days 
controls 
Resolution 
0 P1-13; 3000 
P22-28 
2000 
1000 
Resolution 
Inflation of Antiviral CDS+ T Cell Response 
Results 
The size of anti-viral CD8 T cell response in acute 
hepatitis B 
We initially cvaluated the size and the expansion kinetics of 
CDS T cell population during acute hepatitis B infection. The 
frequency and quantity of CDS T cells expressing CD3S/HLA-
DR and Ki-67 /Bcl-2 phenotypic markers was analyzed in 20 
patients with acute hepatitis B. Samples were collected at multiple 
time points from onset of clisease (HBsAg+, ALT> 1000 U /L) to 
full recovery (HBsAg- at least 1 month after onset). 
A remarkably large expansion of activated CDS T cell pool was 
detected. CD3S/HLA-DR markers were expressed by approxi-
mately a quarter of total CDS T cells (mean 23%, range 12-6S%) 
at the onset of clinical hepatitis. The frequency of CD3S/HLA-
DR+ CDS T cells decreased consistently at the second time point 
(S-10 days later, mean 12%; range 4--22%) and at the time of 
recovery it returned to the normal level (mean 3%, range 0.9-
10% ), detectable in healthy con trois (Figure 1, left panel). CDS T 
cells co-cxpressing Ki-67 and low Bcl-2 followed identical kinetics. 
The peak of Ki-67 /Bcl-2 low CDS T cells was detected at the 
onset of disease (mean 14°/ci, range 4.5-27% of total CDS T) and 
contracted abruptly aller 10 days (mean 5%, range O.S-11 %) and 
at the resolution minimal proliferation was detected (mean O.S%, 
range 0.4--1.6%) (Figure 1, right panel). 
Antigen-specificity of the activated/proliferating CD8 T 
cell population 
To analyze whether the population of activated/proliferating 
CDS T cells included HBV-specific CDS T cells, HBV-specific 
pentamers were used to directly visualize these cells in 5 HLA-
A201 + patients. Figure 2 A and B shows that the expression of 
activation markers of HBV-specific CDS T cells followed the 
kinetics of expression of the total CDS T cell population. HBV-
pentamer+ CDS T cells expressed activation markers and 
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Figure 1. Activated and proliferating CDS T cells during acute hepatitis B infection. Longitudinal CD3S/HLA-DR (left) and Ki-67/Bcl-2 (right) 
expression on total CDS T ce lis in patients with acute HBV infection (n = 20) is shown. Ki-67 /Bcl-2 expression was done in 9 out of 20 patients. FACS 
contour plots were gated on CD3/CDS positive cells. Percentages of double positive cells are shown. The arrow indicates the level of activation/ 
proliferation found in healthy controls (the average of 5). White bars indicate the mean serum ALT levels, shaded area shows the mean serum HBV 
DNA of the patients tested. 
doi:10.1371/journal.ppat.1001051.g001 
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Figure 2. Activation and proliferation of HBV-specific T cells during acute HBV infection. A) CD3S/HLA-DR and Ki-67 expression on HBV 
corel S-27 pentamer +CDS T cells at the onset of disease and after resolution (+35 days) in a representative patient. B) Percentages of HBV-pentamer 
+ CDS T cells expressing CD3S/HLA-DR and Ki-67 in 5 patients over time. 
doi:l 0.1371/journal.ppat.1001051.g002 
proliferated at the onset of diseasc but not at the rccovery phase 
(Figure 2 A and B). These results demonstrate that HBV-specific 
CDS T cells are represented within the total population of 
activated/proliferating total CDS T cells. 
Then we tested whether CDS T cell specific for other common 
viruses (CMV, EBV, influenza) quantitatively contribute to the 
total pool of activated/proliferating CDS T cells. A set of HCJ\1IV, 
EBV or Influenza pentamcrs (Supplementary Table Sl) was used 
to detect CDS T cells specific for these common infections. vVe 
visualized a sizeable ex vivo frequency of HCrvIV, Influenza and 
EBV-spccific CDS T cells in 13 acute hepatitis B patients and their 
expression of CD3S/HLA-DR and Ki-67 was testcd at the onset 
of acute hepatitis and after recovery. 
A remarkably different profile of CDS T cell activation was 
detectcd in relation to the CDS T cell specificity. While influenza-
specific CDS T cells were neither activated (S out ofS patients) nor 
proliferating (5 out of 5 tested patients) at ail time points (Figure 3 
A and Supplementary Figure Sl), HCMV and EBV-specific CDS 
T cells were activated (HCMV mean 12.5%; EBV mean 30%) and 
proliferating (HCrvIV mean 4.9%; EBV mean S%) (Tables 1--2 
and Figure 3 A) in ail the acute HBV patients where such cells 
were detectablc. The expression of CD3S/HLA-DR and Ki-67 
markers in HCrvIV and EBV-specific CDS T cells followed the 
same expression kinetics of total and HBV-specific CDS T cells 
and contracted alter recovery as shown on Figure 3 B (patient 12). 
The differential phenotype of CDS T cells specific for different 
viruses during acute hepatitis B was well represented in a patient 
(patient 10, Supplementary Figure Sl) where the different CDS T 
cells specificities co-exist in different activation states. As already 
shown in Figure 2, at the peak of acute hepatitis, HBV-specific 
·'c®. •. .. 
. .· 
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CDS T cells are mostly activated (77%) and proliferating (65%). At 
the same time point, a proportion ofHCrvIV-specific CDS T cells 
are also expressing activation (20%) and prolifèration (6%) 
markers, while influenza-specific are in a complete resting 
phenotype. Taken together, these data demonstrated that, at least 
in acute hepatitis B infection, a sizable proportion of CDS T cells 
specific for persistent viruses are activatcd during acute heterol-
ogous infection. 
Activated HCMV/EBV specific CD8 T cells during acute 
viral infections 
Evidence of activation of unrelated virus specific CDS T cells 
has been also reported in HIV infection [14], but our results 
clearly differ from the ones obtained in attenuated virus vaccine 
recipients [13], where activation of Influenza, HCrvIV and EBV 
was not reported. Thus we tested whether our observation was 
peculiar to acute HBV infection or whether it represents a 
common feature in other acute viral infections in human. 
Samples from patients with acute Dengue (n 12), Influenza A (n 
12), Adenovirus (n 3) infections were collected at the onset of 
disease (represented in these patients by fever >3S 0 C), after 5-7 
days and after recovery ( ~21 days) and frequency of CDS T cell 
population expressing activation (CD3S/HLA-DR) and prolifer-
ation (Ki-67) markers was measured (Figure 4 A). Differences in 
the magnitude and kinetics among diseases with different etiology 
were found. Adenoviral infection elicited a minimal activation of 
CDS T cell population (mean 3.5%), which is only slightly higher 
than that ofhealthy individuals (mean of 5 healthy contrais 2.4%). 
In addition, the peak frequency of activated total CDS T cells in 
dengue and influenza infections is detected 5-7 days after onset of 
August 2010 1 Volume 6 1 Issue S 1 e1001051 
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Table 1. Activated HBV-, HCMV-, EBV- and Flu-specific CDS T cells in HBV acute patients where HBV, HCMV, EBV and Influenza 
specific cells could be visualized with pentamers. 
Patients (HBV Acute) CD38+/HLA-DR+cD8+ T cells % (absolute number/10 µI) 
Total CDS HBV HCMV EBV FLU 
p 7 1S% (73S) S1% (lOS) 5.5% (2) n f n f 
p 9 1S% (720) 43% (14) 13% (10) n f n f 
p 10 25% (940) 77% (9) 20% (20) n f 0% (0) 
p 11 21% (SOO) S1% (54) n f n f 0.9% (0) 
p 12 2S% (121S) n f S% (9) 41% (12) n f 
p 13 17% (700) n f nf 31% n f 
p 22 17% (700) n f n f nf 2% (0) 
p 23 15% (SSO) n f 12% n f 1.3% (0) 
p 24 26% (1066) S9% 20% n f 1.4% (0) 
p 25 12% (710) n f 9% (10) 26% (9) 0% (0) 
p 26 6S% (n.d.) n f n f 22% (n d) n f 
p 27 16% (n d) n f n f nf 0.2% (n d) 
p 2S 21% (n d) n f n f n f 0% (n d) 
Average 23% 74% 12.5% 30% 0.7% 
Percent of activated virus-specific CDS T cells are shown and the number of cells in 10 µI of blood, calculated based on the pentamer frequency and lymphocyte cou nt 
in the blood of patients at the acute stage. 
n f = not found; n d = not done. 
doi:l 0.1371/journal.ppat.1001051.t001 
fever unlike that of HBV, whcre the peak frequency is seen at the 
onset of disease (Figure 4 A). These different profiles are 
compatible with the fact that the onset of disease in acute hepatitis 
Gaundice) is represented by forer injury and coïncides with the 
Table 2. Proliferating HBV-, HCMV-, EBV- and Flu-specific CDS 
T cells in HBV acute patients where HBV, HCMV, EBV and 
Influenza specific cells could be visualized with pentamers. 
Patients 
(HBV Acute) Ki-67+ CD8+ T cells % (absolute number/10 µI) 
Total CDS HBV HCMV EBV FLU 
p 7 19% (73S) S5% (112) 2% (1) n f n f 
p 9 6% (240) 10% (6) 2.4% (2) n f nf 
p 10 16% (564) 65% (S) 6% (6) n f 0% (0) 
p 11 17% (560) 67% (40) n f n f 0.1% (0) 
p 12 nd n f n d nd n f 
p 13 16% (739) n f 9% (12) 11%(1) n f 
p 22 n d n f n f n f nd 
p 23 nd n f nd n f n f 
p 24 n d nd nd n f nd 
p 25 12% (520) n f nd 5% (0.2) 0% (0) 
p 26 nd n f n f n d n f 
p 27 1S% (n d) n f n f n f 2.5% (n d) 
p 2S 27% (n d) n f n f n f 0% (n d) 
Average 16% 57% 4.9% S% 0% 
Percent of proliferating virus-specific CDS T cells are shown and the number of 
cells in 1 O µI of blood, calculated based on the pentamer frequency and 
lymphocyte count in the blood of patients at the acute stage. 
n f = not found; n d = not done. 
doi:l 0.13 71/journal.ppat.1001051.t002 
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peak of adaptive immune response [15,16] while dengue and 
influenza infections trigger a strong innate immune reaction 
(fèbrile status being a clinical manifestation) and thus, in thesc 
infections, full maturation of virus-specific adaptive immunity is 
expected to peak ~ 5-7 days after infection. 
Nevertheless, despite the lower quantity of total activated CDS 
T cells in dengue, influenza, adenovirus patients as well as in 3 
subjects with fever of unidentified etiology, the CD3S/HLA-DR 
expression profile on HCMV or EBV specific CDS T cells was 
similar to that in acute HBV infèction. Figure 4 B summarizes the 
results obtained in the patients with the indicated pathologies, 
where a sizeable ex vivo frequency of HCiVIV or EBV specific 
CDS T cells was detected. HCiVIV and EBV specific CDS T cells 
(lower panel) express activation markers to a level even higher to 
what is detected in the global CDS T cells populations (upper 
panel). Unfortunately, the paucity of the cells obtained in these 
patients didn't allow us to analyze also Ki-67 expression on 
HCMV and EBV specific CDS T cells, but overall these results 
demonstrate that activation of CDS T cells specific for persistent 
viral infection (HCMV-EBV) is a constitutive fèature of acute anti-
viral immunity in human. 
Interestingly, we were able to study a patient with acute 
influenza infection in whom, influenza-specific CDS T cell 
expansion didn't coincide with the profile of total activated CDS 
T cells (Figure 4 C, P14). In this subject, the influenza-spccific 
CDS T cells (specific for matrix protein 5S-66 epitope) could be 
visualized only 5 days after onsct of symptoms. In contrast, 
HCMV-specific (pp65 123-131) CDS T cell frequency was 
comparatively constant at different time points ( 1. 7 % onset; 
l.S 0/c, +5 days; 1.4% + 14 days), and already co-expressed 
activation markers (30%) at the onset of disease (Figure 4 C). 
Thus, in this patient, the whole CD3S/HLA-DR+ population 
before the expansion of the CDS T cells specific for the acutely 
infected virus seems to be composed of herpesvirus-specific 
activated CDS T cells. 
August 2010 1 Volume 6 1 Issue 8 1 e1001051 
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Figure 4. Activation of CDS T cells in different acute viral infections. A) Kinetics of the expansion of CD38/HLA-DR expressing CD8 T cells in 
acute HBV (n = 20), dengue (n = 12), influenza A (n = 12), adenovirus (n = 3) infected patients. B) Frequencies of total CD8 T (upper panel) and HCMV 
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doi:l 0.1371/journal.ppat.1001051.g004 
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Selective activation of HCMV/EBV-specific CDS T cells by 
IL-15 
vVe investigated the possible mechanisms of the selected 
activation of HCJVIV and EBV- specific CDS T cells in patients 
with heterologous acute viral infections. 
CDS T cell cross-reactivity, reactivation of the HCMV or EBV 
infection and/ or activation mediated by cytokines can be 
implicated in this phenomenon. 
Cross-reactivity between HCJVIV or EBV-specific CDS T cells 
with epitopes present in the acute heterologous virus infection 
seems unlikely. The cross-reactive potential of HCMV-specific 
CDS T cells is very uncommon [7] and our data do not support 
cross-reactive mechanisms either. vVe could detect activation of 
CDS T cells specific for two distinct immediate early and latent 
EBV epitopes (HLA-BS RAKFKQLL, BZLF-1 190-197, and 
HLA-BS FLRGRAYGL, EBNA-3A 193-201) in an acute HBV 
patient (Supplementary Figure S2). If cross-reactivity was 
responsible of this activation, it would require that both epitopes 
share sequence or structural similarity with HBV virus, an unlikely 
scenario, based on a sequence similarity search (NCBI Publ'vled 
BLAST), which demonstrated no sequence overlap (lowest Evalue 
obtained = 11) between these EBV epitopes and HBV proteome. 
Reactivation of HCMV and EBV could be a plausible cause, 
and it might explain why CDS T cells specific for Influenza are not 
activated in acute HBV infections. To investigate this possibility, 
HCJVIV and EBV DNA levels were tested longitudinally in the 
serum. However, we did not find any evidence of HCJ\,IV or EBV 
reactivations. HCJVIV-DNA and EBV-DNA titers were below the 
level of detection in ail patients (HBV, Dengue, Influenza, 
Adenovirus and fever of unidentified etiology) from the onset of 
acute heterologous viral infèctions to recove1y (data not shown). 
Importantly, although HCMV and EBV reactivations are usually 
a~sociated with the expansion of HCMV /EBV- specific CDS T 
cells [l 0, 17, l S] significant changes in the EBV or HCJVIV specific 
T cells quantity were not observed through the course of acute 
infèctions (Figure 3 B and Supplementary Figure S2). 
vVe therefore analyzed whether cytokines produced during 
acute viral infections [19] can be responsible for the differential 
expression of activation markers by EBV-, HCMV- and influenza-
specific CDS T cells. 
PBMC or purified CDS T cells of healthy subjects containing 
resting EBV, HCMV and Influenza specific CDS T cells werc 
incubated with different concentrations of IL-15, IL-2, IL-7, IFN-
y, IFN-o: and TNF-o: and the expression of HLA-DR and CD3S 
on EBV, HCMV and Influenza specific CDS T was analyzed at 
different intervals (Figure 5 A). We detected that after 24 and 
4S hours of incubation, IL-15 (at l and 10 ng/ml) induced CD3S/ 
HLA-DR expression in HCMV and EBV specific CDS T cells 
while the other inflammatory cytokines did not activate EBV and 
HCMV spccific CDS T cells. Similar to the in vivo findings, 
influenza-specific CDS T cells wcre not or only weakly activated 
by addition of any of the tested cytokines (Figure 5 A and B). 
Prolonged incubation times (3 to 5 days) did not alter the 
activation profile. Figure 5 B shows the results obtained in one 
healthy subject where HCMV, EBV and Influenza specific CDS T 
cells were simultaneously detected. Incubation of total PBJVIC with 
IL-15 induces expression of CD3S/HLA-DR molecules in EBV 
and HCMV specific CDS T cells (44% and 37% respectively) but 
only in few influenza-specific CDS T cells (7°/ci). The specific effect 
ofIL-15 on HCJVIV and EBV-specific CDS T cells was confirmed 
in other healthy subjects where individual specificities were 
detected (HCJVIV = n4; EBV = n4). Similar results were obtained 
incubating total PBMC or CD3+ CDS+ purified cells (not shown). 
Thus, IL-15, a cytokine that has been shown to induce T cell 
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activation in mice [20] and human [21,22] and is known to be 
produced during acute viral infections ([19] and persona! data) 
induces preferential CD3S, HLA-DR up-regulation of HCJVIV 
and EBV-specific CDS T cells rather than influenza-specific ones. 
Functional analysis of HCMV and EBV-specific CDS T cells 
during acute heterologous viral infections 
Having observed that a proportion ofHCMV and EBV-specific 
CDS T cells are activated during heterologous acute viral 
infection, we sought to analyze their functional profile. The 
limited quantity of cells available in patients with acute viral 
infections precludes an extensive evaluation of the functional 
profile directly in our patient sample. Thus, since IL-15 mimics the 
differential activation state ofHCMV, EBV and influenza-specific 
CDS detected in patients with acute viral infections, we performed 
a series of functional experiments using PBJVIC of healthy 
individuals activated with IL-15. 
We first tested whether IL-15 can differentially trigger T cell 
activation in HCMV, EBV and Influenza specific CDS T cells in 
vitro. PBMC ofhealthy individuals were incubated with or without 
IL-15 for 4S hours and HCMV, EBV and influenza-specific CDS 
T cells were tested for their ability to produce anti-viral cytokines 
(IFN-gamma, IL-2 and TNF-alpha) using intracellular cytokine 
staining. Note that the cytokines measurement on CDS T cells 
specific for the different viruses requires their visualization with the 
specific HLA-class I/peptides pentameric complex (pentamers). 
The pentamer staining can potentially trigger T cell stimulation 
through direct interaction of the TCR with the synthetic MHC-
class I peptide complexes of the pentamers[23,24,25]. Thus, to 
distinguish whether IL-15 can directly trigger T cell activation 
(TCR-independent stimulation) or enhance the T cell activation 
triggered by MHC/peptide pentamer (TCR-dependent stimula-
tion), the intracellular production of IFN-gamma on CDS T cells 
was analyzed adding the MHC/peptide pentamers either before 
(TCR-dependent stimulation) or after (TCR-indepcndent stimu-
lation) the incubation time of intracellular cytokine staining. A 
schematic reprcsentation of the expcrimental design is presented in 
Figure 6 A. 
In accordance with previous studies [21,22], IL-15 elicited a 
spontaneous production of IFN-gamma on T cells. However, the 
level of IFN-gamma production was modest and present in CDS 
cells irrespective oftheir specificity. Dot plots displayed in Figure 6 
A illustrate these results obtained in one representative subject. 
Increased production of other cytokines (IL-2, TNF-alfa) was Jess 
striking (not shown). 
In contrast, we observed that HCJVIV and EBV-specific CDS T 
cells incubated with IL-15 and staincd with MHC/peptide 
pentamer at the beginning of the intracellular cytokine assay 
showed an increased ability to produce IFN-gamma. More than 
70% of IL-15 pulsed HCMV and EBV-specific CDS T cells 
produced high quantity ofIFN-gamma while in the absence ofIL-
15, MHC-pentamer staining stimulate only a minority of HCMV 
and EBV-specific CDS cells (Figure 6 A-B). Importantly, IL-15 
incubation has a modest effect on Influenza specific CDS T cells 
(Figure 6 A-B). Thus, our in vitro expcriments showed that IL-15 
is not only able to preferentially activate HCMV and EBV-specific 
CDS T cells, but can also modulate their fimctional responsiveness 
to the TCR-dependent stimulation mediated by MHC-pentamer 
staining. 
Having defined a different functional profile on in vitro activated 
HCMV and EBV-specific CDS T cells, we tested whether such 
features could be detected in vivo. 
In line with the experiments in vitro, MHC-peptide pentamer 
stimulation was detected preferentially on HCMV and EBV-
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Figure 5. IL-15 induced activation of HCMV and EBV-specific CDS T cells. A) PBMC of 4 healthy volunteers were incubated with IL-15 (10 ng/ 
ml), IL-2 (20 U/ml), IL-7 (10 ng/ml), IFN-y (100 U/ml), IFN- cr (100 U/ml), TNF- cr (100 U/ml). Cells were harvested at the indicated time points and 
frequency of CD38/HLA-DR expressing virus specific COB T cells was analyzed. B) Contour plots show the CD38/HLA-DR expression of EBV, HCMV or 
Influenza specific COB T cells after 48 hours of incubation with the indicated cytokines in a representative healthy subject. 
doi:l O. 1371/journal.ppat.1001051.g005 
specific CDS cells present during the acute phase ofHBV infection 
(Figure 6 C and D). 
Figure 6 C shows the results obtained in a representative patient 
(P24) with acute hepatitis and with a sizeable population of 
activated HCrvIV-specific CDS T cells (20%). While the 
spontaneous production ofIFN-gamma was identical in HCrvIV-
specific CDS cells present at the onset and at recovety of acute 
hepatitis B (Figure 6 C- unstimulated), 12% of HCMV specific 
CDS cells present at the onset of acute hepatitis B against only 4°/c, 
of the ones present at recovery produced IFN-gamma after MHC-
pentamer stimulation (Figure 6 C). In addition to the higher 
frequency of IFN-gamma producing cells, the amount of the 
cytokine produced during the onset was higher than that during 
the resolution, as visualized by the difference in mean fluorescence 
intensity (MFI) (1152 at onset and 507 resolution). 
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Figure 6 B shows the cumulative results obtained in 6 subjects 
with detectablc HCMV (P9, PIO, P7, P2't), EBV- (P13) and 
influenza-specific CDS (P24, Pl 1) at the onset and recove1y of 
acutc hepatitis B. Bars indicatc the 'X, increase of IFN-gamma 
producing CDS T cells at onset of acute hepatitis in comparison 
with recovety. 
Thus, pèrsistent virus specific CDS T cells produce more anti-
viral cytokines after TCR-mediated activation during acute phase 
of heterologous viral infection. 
Discussion 
vVe demonstrate here that activation of CDS T cells specific for 
persistent viral infection (HCrvIV-EBV) is a constitutive feature of 
acute anti-viral immunity in human. 
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representation of experimental design: PBMC from healthy volunteers were incubated for 4S h in presence or absence of IL-15. Cells were then 
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Our conclusions differ from the ones obtained in attenuated 
virus recipients [13], which have suggested that activated (CD3S/ 
HLA-DR+) and proliferating (Ki-67+) CDS T cells are exclusively 
constituted of CDS T cells specific for the acutely infecting virus. 
However, our patients with activated/proliferating HCMV and 
EBV responses had a symptomatic viral infection with a high level 
of inflammation, whereas those subjects vaccinated with attenu-
ated viruses, by definition, should not exhibit any pathology of 
acute infection. 
Of note, the presence of activated HCMV and EBV specific 
CDS was also detected during other pathological human viral 
infections [14,26,27] further supporting our conclusion that 
activation of CDS T cells specific for persistent infection is a 
consistent phenomenon during symptomatic viral infections. 
In contrast to HCMV and EBV-specific CDS cells, we 
observed that CDS T cells specific for influenza were not 
activated during the acute phase of heterologous acute viral 
infection. Thus, our data show that memory CDS cells specific 
for persistent and non-persistent viruses not only differs in term of 
phenotypic profile in healthy individuals [2SJ, but respond 
differently to the pathological condition triggered by an 
heterologous acute viral infection. 
vVe can only speculate about the causes of the variable behavior 
of CDS T cells specific for the different pathogens. A plausible 
explanation is that, while influenza-specific CDS T cells are true 
memory CDS cells without any recent encounter to their specific 
ligand, EBV and HCJ'vIV specific CDS cells might experience a 
continuons or repetitive exposure to the specific antigens. 
The accumulation over time of herpesvirus-specific CDS T cells 
in healthy subjects [29,30] and work in animal mode! of HCMV 
infection [31], have suggested that EBV and HCMV antigens are 
constantly available for T cell stimulation. The Ag-exposure might 
modulate the fünctional state of HCJ'vIV and EBV-specific CDS 
cells and program them to respond to cytokines produced during 
acute viral infections. The difierential functional state of 
herpesvirus specific CDS T cells when compared with influenza-
specific was confirmed by our in vitro data. vVe clearly demonstrate 
that IL-15 triggers in vitro the activation/proliferation ofHCMV, 
EBV specific rather than influenza-specific CDS T cells. 
Based on these in vitro data, we favor the idea that the detection of 
activated/proliferating HCJ'vIV and EBV specific CDS T cell is 
mediated principally by the presence of IL-15 during acute phase of 
viral infections. This makes HCJ'vIV /EBV reactivation or indeecl 
cross-reactivity a less likely explanation for this phenomenon. 
However, it is important to stress that this causative link is 
hypothetical since the level ofIL-15 requirecl to activate HCJ'vIV / 
EBV in vitro (1-10 ng/ml) is higher than what we cletectecl in the 
serum of the patients in this stucly (always lower then 50 pg/ml in any 
viral infection, data not shown). Such inconsistency should be taken 
into account, even though the serum cytokine levels cannot clefine 
their actual concentrations in the target organ or lymph nocle. 
We cannot exclucle that a reactivation of EBV /HCiVIV 
infection is occurring in our patient population and thus clirectly 
clriving the HCJ'vIV or EBV-specific CDS T cell activation. We 
coulcln't clemonstrate any virological eviclence of HCiVIV and 
EBV reactivation, but the negative virological tests do not exclude 
a HCMV and/or EBV viral reactivation is present elsewhere 
outsicle the bloocl compartment and is immecliately curtailecl by 
activatecl HCJ'vIV and EBV specific CDS T cells. A similar 
scenario was suggested to occur in patients with acute Hantavirus 
infection where an increasecl EBV-DNA titers were founcl only in 
subjects without measurable EBV-specific T cell response [26]. 
However, it has been reportecl that HCMV and EBV reactivation 
is associatecl with the expansion of HCJ'vIV /EBV specific CDS T 
·'@). '. .. 
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cells [10,17,lS], which was not observecl in any of our patients 
(Figure 3 B and Supplementary Figure S2). 
\i\lhat appears clear from our datais that the contribution of the 
activatecl/proliferating HCiVIV /EBV specific CDS T to the size of 
activatecl total CDS T cells is not negligible, but at the contrary 
can alter the quantitative measurement of anti-viral CDS T 
response cluring acute viral infections. A mean of; respectively, 
30% and 12.5% ofEBV and HCMV-specific CDS T cells express 
activation markers cluring the acute phase of different viral 
infections and since the combinecl population of bath HCJ'vIV-
EBV specific CDS T cells might exceecl 20% of total CDS T cells 
[7,9] it is plausible to conclucle that EBV /HCJ'vIV-specific CDS T 
cells can inflate the number of total activatecl CDS T cells. 
The presence of activatecl/proliferating CDS T cells specific for 
HCMV and EBV during the early phases of clifferent acute viral 
infection raises several questions. First, it will be interesting to 
evaluate whether CDS T cells specific for other persistent viruses 
(i.e. HSVl and 2) can actually behave like HCJ'vIV or EBV specific 
CDS T cells and thus further contribute to the anti-viral CDS T 
cell acute response. 
A further question might aclclress the biological significance of 
the herpesvirus specific CDS T ce!! activation during heterologous 
acute viral infections. 
There is a possibility that the activation/proliferation state of 
HCMV /EBV specific CDS T cells counteracts the potential 
attrition exerted by the expansion of CDS T cells specific for the 
acutely infecting virus [32] and therefore might be important for 
preventing the reactivation of HCMV /EBV infection. In this 
regard, our data cliffer from previous reports in acute HBV 
infectecl patients [33], since we clic! not observe any significant loss 
ofHCJ'vIV or EBV specific CDS T cells. On the contrary, HCMV 
and EBV-specific CDS T cell frequency was remarkably constant 
cluring the clifferent phases of acute heterologous viral infèctions 
and the observecl milcl proliferation of HCMV and EBV specific 
CDS T cells (Figure 3 A and Supplementa1y Figure S2) might 
represent a compensatory mechanism counteracting the attrition 
exerted by the expansion of CDS T cell specific for the acutely 
infecte cl virus [30, 34]. 
In addition, the observation that activation ofHCMV and EBV 
specific CDS T cells present during the acute phase of 
heterologous viral infections is associatecl with a functional 
increase in the MHC-pentamer mecliatecl CDS T cell activation 
further supports the iclca that such events might have a broacler 
biological significance. 
vVe can only speculate about the physiological significance of 
the incrcasecl MHC-pentamer mecliatecl CDS T cell activation. 
However, a plausible interpretation is that the HCMV and EBV-
specific CDS cells during acute heterologous viral infection are less 
clepenclent to possible co-stimulatory effect mecliatecl by aclclitional 
molecules proviclecl by their target cluring T cell recognition. 
Altcrnatively, the increasecl response to pentamer-mecliatecl 
staining might inclicate a lower requirement of MHC-class I 
complexes necessaiy for T cell activation [24]. These varions 
possibilities will neecl further investigation, but what our data 
clearly clemonstrate is that functional clifferences in the ability to 
procluce IFN-gamma are present in clifferent phases of heterolo-
gous acute viral infection. 
The increasecl likelihoocl ofactivatecl HCMV, EBV specific CDS 
T cells to procluce antiviral cytokines after recognition of HCMV 
and EBV antigens might be beneficial not only in the contra! of 
HCMV /EBV reactivation but can actively contribute to the global 
anti-viral immune response. Evidences in animal mode! have 
alreacly shown that T cell activation of non-antigen specific T cells 
can contribute to the early response against pathogens [12,35]. 
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On the other hand, the detected hyper-responsiveness of 
HCivIV and EBV- specific CDS T cells can have an impact on 
immunopathogenesis of the viral infections [36]. Heterologous 
immunity have been observed to alter pathogenesis of different 
viral diseases [37,3S]. 
ln conclusion, we show that the CDS T cell population 
activated during acute viral infection is not constituted exclusively 
by CDS T cells specific for the newly infected virus. On the 
contrary, this population is inflated by the presence of activated T 
cells specific for herpesvirus, directly demonstrating the ability of 
persistent virus infections to leave a functional imprint on the acute 
anti-viral T cell response in humans with functional consequences 
that will require further elucidation. 
Methods 
Patients and samples 
Sam pies were taken from patients or healthy volunteers attending 
clinics in Singapore (Dengue, Influenza, Adenovirus infections, 
fevers of unidentified etiology and healthy volunteers) and ltaly 
(HBV infection). Local Review board and Ethical Committees 
approved the study. Total number of patients is 50: HBV 20, 
Influenza 12, Dengue 12, Adenovirus 3, patients with fevers of 
unidentified ctiology 3. Number ofhealthy volunteers enrolled is 5. 
Age of the subjects ranged from 20 to 54 years old. Patients were 
selected on the basis of fever >38°C (Dengue, Influenza, 
Adenovirus) or jaundice (HBV). Diagnosis of dengue (detection of 
dengue virus by PCR), influenza A(+ isolation of influenza A from 
nasal swab), adenovirus (isolation of the virus from nasal swab), and 
HBV (HBsAg +, anti-HBc IgM+ and HBV-DNA+) was performed 
within 5 days from selection. Acute hepatitis B patients were all 
HBsAg+ and had ALT> 1000 U /L, at the disease onset. Ail healthy 
volunteers were asymptomatic. Peripheral blood mononuclear ce!! 
isolation from whole heparinized or EDTA blood with Ficoll-
Hypaque was performed within 4 hours of drawing. PBMC were 
analyzed immediately or frozen for subsequent analysis. 
Virological measurements 
HBV patients: HBsAg, HBeAg, anti-HBs, anti-HBc IgG and 
IgM, anti-HBe, anti-HDV, anti-HCV, anti-HIV-1 and -2 were 
determined by commercial enzyme immunoassay kits (Abbott Labs, 
IL, USA; Ortho Clinical Diagnostic,Johnson &Johnson, DiaSorin, 
Vercelli, Italy). HBV-DNA was quantified by PCR (Gobas 
Amplicor test; Roche Diagnostic, Base!, CH) and CMV-DNA was 
quantified with artus-CMV-LC PCR (Qiagen, Qiagen Gmbh, 
Hilden), EBV-DNA was tested with EBV R-gene DNA extraction 
and quantification kit (Argene, Varilhes, France). Dengue detection 
was performed by RNA isolation from serum samples using RNA 
extraction kit followed by reverse-transcription into cDNA 
(Superscript III First Strand kit, Invitrogen, California, USA). The 
cDNA was PCR amplified for detection of the virus, for 
determination of serotype and for quantification of viral load as 
previously published [39]. The serum and nasal swab samples were 
tested for the presence of Influenza A and Adenovirus using R T-
PCR (Superscript III First Strand kit, Invitrogen, California, USA) 
and direct immunofluorescence assay on nasal swabs (Light 
Diagnostic Influenza A antibody FITC reagent, Millipore, Billerica, 
J\!IA). Amino acid sequence alignment was clone using BLAST from 
NCBI PubMed (http:/ /blast.ncbi.nlm.nih.gov/Blast.cgi). 
Reagents 
HLA-peptide pentameric complexes (pentamers) were pur-
chased from Proimmune (Oxford, UK). Anti-CDS (PE-Cy7 and 
APC-Cy7), anti-CD3 (perCP and perCP-Cy5.5) anti-CD3S (APC), 
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anti-HLA-DR (Pe-Cy7), anti-KI-67 (FITC and PE), anti-Bcl-2 
(FITC), anti-IFN-y (FITC and APC), anti-IL2 (FITC, PE and 
APC), and isotype contrai antibodies were purchased from BD 
Biosciences, San Jose, CA. 
Phenotypic analysis 
Titrated pentamers (PE) were added to 50 µ! of purified PBMC 
(2 x 106 cells total) for 15 min at 25 °C in the dark, washed and then 
panel of titrated antibodies for surface markers were added to 
pentamer stained or total PBivIC. The cells were then fixed and 
permeabilized using Cytofix/Cytoperm solution (BD Biosciences, 
SanJose, CA). After washing, intracellular staining was performed 
for intracellular markers (Ki-67, Bcl-2). Cells were then washed 
3 times, and fixed with 1 % formaldehyde before acquisition on a 
FACS Canto flow cytometer. Compensation was checked 
regularly using F ASC Diva software. Compensation con trois were 
individually determined for each experimental setup. 
Functional assays 
PBMC were stained with the relevant pentamcrs (MHC/ 
peptide pentamer stimulated), or left unstained (unstimulated), 
washed and then incubated for 5 h with 10 µg/ml brefeldin A 
(Sigma-Aldrich, St. Louis, MO). Following incubation, the 
unstimualted cells were stained with relevant pentamers and 
MHC/peptide pentamer-stimulated were left in PBS. Then cells 
were stained with anti-CDS and anti-CD3 mAbs for 20 min at 
4°C then fixed and permeabilized using Cytofix/Cytoperm 
solution. Finally, cells were stained with anti-IFN-y and anti-IL-
2 for 30 min on ice, washed, and foced with 1 % formaldehyde 
before acquisition on a FACS Canto flow cytometer. For analysis 
of anti-virus-specific CDS T activation in vitro, freshly isolated 
PBMC or purified CDS+ T cells were incubated in vitro at 
2xl06/ml with or without cytokines (IL-7, IL-2, IL-15, IFN-y, 
IFN- a, TNF- a, purchasecl from RnD Systems, Ivlinneapolis, 
MN). The cells were collectecl at indicated time points, and the 
intracellular cytokine staining was performed as clescribed above. 
Ethics statement 
This stucly was conductecl according to the principles expressed 
in the Declaration of Helsinki. The study was approved by the 
lnstitutional Review Board of Singapore National Healthcarc 
Group Ethical Domain and Azienda Ospedalicra Universitaria di 
Parma Ethical Committee hospitals. Ali patients provided written 
informcd consent for the collection of samples and subsequent 
analysis. 
Supporting Information 
Figure SI Differcnt activation markers expression profùcs of 
Influenza, HCivIV-specific and HBV-specific CDS+ cclls present 
in a representative patient at the onset of acute hepatitis B. 
Found at: cloi: I0.1371/journal.ppat.1001051.sOOI (1.28 MB TIF) 
Figure 82 A) Quantity of CJ\!IV, EBV and Flu specific CDS T 
cells do not change during heterologous acute viral infections. 
PBivICs of acute HBV and Influenza patients from three time 
points of the disease were stained with pentamers specific for 
CMV, EBV and Flu and with anti-CD3, anti-CDS monoclonal 
antibodies. The quantity of pentamer+ cells were determined 
based on the frequency of pentamer CDS T cells and the 
lymphocyte counts. B) Activation of two distinct epitopes of EBV 
during acute hepatitis B. PBMCs of acute HBV patient were 
stained with two EBV pentamers (BZLFl 190-197 and EBNA3A 
193-201) and CD3, CDS, CD3S, HLA-DR surface markers. 
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Found at: doi:l0.1371/journal.ppat.1001051.s002 (1.26 MB TIF) 
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DOC) 
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doi: 10.1371/journal.ppat. l OO 105 l.s003 (0.03 MB 
References 
1. Schaub B, Lauener R, von J\fotius E (2006) The many faces of the hygiene 
hypothesis. J Allergy Clin Immunol 117: 969--977. 
2. Barion ES, White DW, CathelynJS, Brett-lvkClellan KA, Engle M, et al. (2007) 
Herpesvirus latcncy confcrs syrnbiotic protection from bactcrial infection. 
Nature 447: 326-329. 
3. Young LS, Rickinson AB (2004) Epstein-Barr virus: 40 years on. Nature Review 
Cancer •I: 757-76S. 
4. Crough T, Khanna R (2009) Immunobiology of human cytomegalovirus: from 
bcnch to bcdsizc. Clinical Microbiology Review 22: 76-9S. 
5. Wang EC, Moss PA, Frodsham P, Lehner PJ, Bell JI, et al. (1995) 
CDShighCD57+ T lymphocytes in normal, healthy individuals are oligoclonal 
and respond to human cytomegalovirus. J Immunol 155: 5046-5056. 
6. Kuijpern TW, Vossen MT, Gent M-R, Davin JC, Roos MT, et al. (2003) 
Frequcncics of Cireulaùng Cytolytic, CD45RA+CD27-, CDS+ T Lymphocytes 
Dcpend on Infection with CMV. Jimmunol 1 70: 4342-434S. 
7. Sylwester AW, Mitchell BL, Edgar JB, Taormina C, Peltc C, et al. (2005) 
Broadly targcted human cytomegalovirus-spccific CD4+ and CDS+ T cells 
dominate the mcmory compartment'l of cxposed subjects. J Exp i\1Icd 202: 
673-6S5. 
S. Kahn N, Hislop AD, Gudgeon NH, Cobbold i'vf, Khanna R, et al. (2004) 
Herpesvirus-specific CDS T cell immunity in old age: cytomegalovirus impairs 
the response to a coresident EBV infèction. J Immunol 173: 74Sl-74S9. 
9. Tan L, Gudgeon N, Annels N, Hansasuta P, O'Callaghan C, et al. (1999) Are-
cvaluation of the frequency of CDS+ T cells specific for EBV in healthy virus 
carriers. J Immunol 162: IS27-IS35. 
10. Polie B, Hcngel H, Krmpotic A, TrgovcichJ, Pavie I, et al. (199S) Hierarchical 
and Redundant Lymphocyte Subsct Contrai Precludes Cytomcgalovirus 
Rcplication during Latent lnfèction.JExp lvfed \SS: 1047-1054. 
11. Gillespie GM, Wills MR, Appay V, O'Callaghan C, Murphy M, et al. (2000) 
Functional hctcrogcncity and high frequencics of cytomegalovirus-specific 
CDS(+) T lymphocytes in healthy scropositive donors. J Virol H: 81 +-824. 
12. Berg RE, Crosslcy E, Murray S, FormanJ (2003) Mcmory CDS+ T cells provide 
innatc immune protection against Listeria 1nonocytogenes in the absence of 
cognate antigcn. J Exp lvfcd 198: 1583 1593. 
13. Miller JD, van der Most RG, Akondy RS, GlidcwcllJT, Albott S, et al. (2008) 
Human effcctor and memory CDS+ T cell responses to smallpox and yellow 
fover vaccines. Immunity 2S: 710-722. 
14. Doisne .JM, Urrutia A, Lacabaratz-Porret C, Gmrjard C, Meyer L, et al. (2004) 
CDS+ T Cclls Specifie for EBV, Cytomegalovirus, and Influenza Virus Are 
Activated during Primary HIV lnfcction.Jimmunol 173: 2410-2418. 
15. Bertolctti A, Gehring 1\J (2006) The immune response during hepatitis B virus 
infection.] Gen Virol S7: 1439 14'19. 
16. Webster G, Reignat S, Maini M, Whalley S, Ogg G, et al. (2000) Incubation 
phase of acute Hepatitis B in man: dynamic of cellular immune 1nechanism. 
Hepatology 32: 1117-l l 2•f. 
17. Clave E, Agbalika F, Bajzik V, Peffault de Latour R, Trillard M, et al. (2004) 
Epstein-Barr virus (EBV) reactivation in allogenic stem-cell transplantation: 
relationship between viral Ioda, EBV-specifc T cell reconstitution and rituximab 
therapy. Transplantation 15: 76-84. 
IS. Savoldo B, GossJA, Hammer .MM, Zhang L, Lopez T, et al. (2006) Treatment 
of solid organ transplant recipicnts with auto1ogous Epstein Barr virus-specific 
cytotoxic T lymphocytes (CTLs). Blood 1 OS: 2942 2949. 
19. Dmm C, Peppa D, Khanna P, Ncbbia G, Joncs lvf, et al. (2009) Temporal 
Analysis of Early Irnmune Responses in Patients \Vith Acute Hepatitis B Virus 
Infection. Gastroenterology. 
20. Sprent .J, Zhang X, Sun S, Tough D (2000) T-cell proliferation in vivo and the 
role of cytokines. Philos Trans R Soc Lond B Bio! Sei 355: 317-322. 
21. Liu K, Catalfamo M, Li Y, Hcnkart PA, Weng NP (2002) IL-15 mimics T cell 
reccptor crosslinking in the induction of cellular proliferation, gene expression, 
··@)· " .. 
· .. ·· 
PLoS Pathogens 1 www.plospathogens.org 12 
Inflation of Antiviral CD8+ T Cell Response 
Author Contributions 
Conceived and designed the experiments: ES AB. Performed the 
experiments: ES DL CB ATT RC BSS. Analyzed the data: ES DL CB 
ATT BSS AB. Contributed reagents/materials/analysis tools: KF EEO CF 
AB. Wrote the paper: ES AB. 
and cytotoxicity in CDS+ memmy T cells. Proc Nat! Acad Sei U S A 99: 
6192-6197. 
22. von Geldcrn M, Simm B, Braun M, Weiss EH, Schendel DJ, et al. (2006) TCR-
independent cytokine stimulation induces non-fi1IHC-restricted T cell activity 
and is negatively regulatcd by HLA class L Eur J Immunol 36: 234 7-235S. 
23. Xu XN, Screaton GR (2002) MHC/peptide tctramer-based studies of T ccll 
fonction. J lmmunol Methods 26S: 21- 2S. 
N. Boniface JJ, Rabinowitz JD, Wulfing C, Hampl J, Reich Z, et al. (199S) 
Initiation of signal transduction through the T cell rcceptor requires the 
mutlivalent engagmcnt of peptide/MHC ligands. Immunity 9: 459--46S. 
25. Appay V, Rowland-Joncs SL (2002) The assessment of antigen-specific CDS+ T 
cells through the combination of ~1IHC class 1 tetramer and intracellular 
staining.J Immunol Methods 268: 9-19. 
26. Tuumincn T, Kekalainen E, Makela S, Ala-Houhala I, Ennis FA, et al. (2007) 
Human CDS+ T cell memmy generation in Puumala hantavirus infection 
occurs after the acute phase and is associated with boosting of EBV-specific 
CDS+ memory T cells. J Immunol 179: 19SS-1995. 
27. Papagno L, Spina CA, Marchant A, Salio M, Rufer N, et al. (2004) Immune 
activation and CD8+ T cell differentiation towards senescencc in HIV-1 
infection. PloS Biology 2: 173 -IS5. 
2S. Appay V, Dunbar PR, Callan M, Klcncrman P, Gillespie GM, et al. (2002) 
lvlemory CD8+ T cells vaiy in differentiation phenotype in dinèrent persistent 
virns infections. Nat Mcd S: 379--3S5. 
29. Wcekes MP, Wills MR, Mynard K, Carmichael f\J, Sissons JG (1999) The 
memory cytotoxic T-lymphocyte (CTL) response to Human Cytomegalovirus 
Infection contains individual pcptide-spccific CTL clones that have undergone 
extensive expansion in vivo.J Viral 73: 2099-2108. 
30. Gamadia LE, van Leeuwen ElvL.\11, Remmcrswaal EB, Y ong SL, Surachno S, et 
al. (2004) The size and phenotype of virus-specific T eell populations is 
determined by repetitive antigenic stimulation and environmental cytokines. 
Jimmunol 172: 6107-611•[. 
31. Karrer U, Sierro S, Wagner M, Oxenius A, Hengel H, et al. (2003) Mcmmy 
inflation: continuons accumulation of antiviral CDS+ T cclls over time. 
J Immunol 170: 2022-2029. 
32. Selin L, Lin MY, Krammer KA, Pardoll D, SehncckJ, et al. (1999) Attrition ofT 
cell memmy: selectivc loss of LCivIV epitope-specific memmy CDS T cells 
following infections with heterologous viruses. Immunity 11: 733-- 742. 
33. Zhang JY, Zhang Z, Jin B, Zhang SY, Zhou CB, et al. (2008) Cutting edge: 
programmcd Death-1 up regulation is involved in the attrition of cytomegalo-
virus-specific CD8+ T cells in acute sclf-limited hepatitis Il virus infection. 
J Immunol !SI: 3741-3744. 
34. van Leeuwen Efiil, Gamadia LE, Baars PA, Remmcrswaal EB, tcn Berge U, et 
al. (2002) Prolifcration rcquirements of cytomegalovirus-specific, effcctor-type 
human CDS+ T cells. J Immunol 169: 5S3S-5S43. 
35. JiangJ, Lau LL, Shen H (2003) Selcctive deplction of nonspecific T cclls during 
the early stage of immune responses to infection. J Immunol 171: •i352--435S. 
36. Selin L, Varga S, Wong I, Welsh R ( l 99S) Proteetivc hctcrologous antiviral 
immunity and enhanced immunopathogenesis mediated by memory T cell 
populations.J Exp Mcd 188: 1705-1715. 
37. Chcn HD, Fraire AE, Joris I, Brchm MA, Welsh füvf, et al. (2001) lvfcmmy 
CDB+ T cclls in heterologous antiviral immunity and immunopathology in the 
lung. Nat Immunol 2: 1067 1076. 
38. Wclsh RM, Sclin LK (2002) No one is naive: the significanee ofheterologous T-
ccll immunity. Nat Rcv Immunol 2: 417 426. 
39. Lai YL, Clnmg YK, Tan HC, Yap HF, Yap G, et al. (2007) Cost-cffeetivc Real-
time reverse transcriptse (RT-PCR) to screen for dengue virus followed by rapid 
single-tube multiplex RT-PCR for serotyping of the virus.J Clin Microbiol •i5: 
935 941. 
Bibliothèque Universitaire 
de Médecine / BiUM 
CHUV-BH08 - Bugnon 46 
CH-i011 Lausanne 
August 2010 l Volume 6 1 Issue 8 1 e10010S1 
